Theravance Biopharma (TBPH) News Today $9.41 -0.04 (-0.42%) Closing price 05/21/2025 04:00 PM EasternExtended Trading$9.41 0.00 (0.00%) As of 05/21/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TBPH Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Theravance Biopharma at H.C. Wainwright: Strategic Focus on YUPELRI and AmpreloxetineMay 21 at 9:30 PM | investing.comD. E. Shaw & Co. Inc. Grows Position in Theravance Biopharma, Inc. (NASDAQ:TBPH)D. E. Shaw & Co. Inc. raised its holdings in shares of Theravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) by 9.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 833,943 shares of the biopharmaceutical companMay 18, 2025 | marketbeat.comJacobs Levy Equity Management Inc. Cuts Stock Position in Theravance Biopharma, Inc. (NASDAQ:TBPH)Jacobs Levy Equity Management Inc. lessened its stake in shares of Theravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) by 23.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 438,463 shares of the biopharmaceuticMay 17, 2025 | marketbeat.comTheravance Biopharma (NASDAQ:TBPH) Upgraded at StockNews.comMay 17, 2025 | americanbankingnews.comNewtyn Management LLC Grows Stock Position in Theravance Biopharma, Inc. (NASDAQ:TBPH)Newtyn Management LLC increased its position in shares of Theravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) by 5.7% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 4,757,403 shares of the biopharmaceutical company's sMay 16, 2025 | marketbeat.comDimensional Fund Advisors LP Acquires 95,304 Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH)Dimensional Fund Advisors LP grew its holdings in shares of Theravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) by 20.8% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 553,713 shares of the biopharmaceMay 15, 2025 | marketbeat.comTheravance Biopharma to Participate in an Upcoming Investor ConferenceMay 13, 2025 | prnewswire.comAnalysts Offer Insights on Healthcare Companies: ALX Oncology Holdings (ALXO), Collegium Pharmaceutical (COLL) and Theravance Biopharma (TBPH)May 11, 2025 | theglobeandmail.comEarnings call transcript: Theravance Biopharma misses Q1 2025 EPS forecastMay 10, 2025 | uk.investing.comTheravance Biopharma, Inc. (NASDAQ:TBPH) Q1 2025 Earnings Call TranscriptMay 10, 2025 | msn.comTheravance Biopharma, Inc. (TBPH) Q1 2025 Earnings Call TranscriptMay 10, 2025 | seekingalpha.comTheravance Biopharma Announces Ampreloxetine Presentations at the International MSA CongressMay 9, 2025 | prnewswire.comCorton Capital Inc. Purchases Shares of 33,346 Theravance Biopharma, Inc. (NASDAQ:TBPH)Corton Capital Inc. acquired a new position in shares of Theravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 33,346 shares of the biopharmaceutical comMay 9, 2025 | marketbeat.comTheravance Biopharma, Inc. Reports First Quarter 2025 Financial Results and Provides Corporate UpdateMay 8, 2025 | prnewswire.comPDT Partners LLC Sells 49,501 Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH)PDT Partners LLC trimmed its holdings in Theravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) by 56.8% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 37,676 shares of the biopharmaceutical company'sMay 5, 2025 | marketbeat.comMarshall Wace LLP Has $622,000 Stock Holdings in Theravance Biopharma, Inc. (NASDAQ:TBPH)Marshall Wace LLP decreased its stake in shares of Theravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) by 56.0% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 66,067 shares of the bioMay 5, 2025 | marketbeat.comTheravance Biopharma (TBPH) Expected to Announce Quarterly Earnings on ThursdayTheravance Biopharma (NASDAQ:TBPH) will be releasing its Q1 2025 earnings before the market opens on Thursday, May 8. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-8-theravance-biopharma-inc-stock/)May 3, 2025 | marketbeat.comPark West Asset Management LLC Cuts Stock Position in Theravance Biopharma, Inc. (NASDAQ:TBPH)Park West Asset Management LLC trimmed its position in shares of Theravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) by 3.8% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,792,988 shares of the biopharmaceutical compMay 1, 2025 | marketbeat.comZacks Research Issues Positive Outlook for TBPH EarningsTheravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) - Analysts at Zacks Research boosted their Q1 2027 earnings estimates for Theravance Biopharma in a report issued on Wednesday, April 23rd. Zacks Research analyst R. Department now expects that the biopharmaceutical company will earn ($0.40)April 29, 2025 | marketbeat.comTheravance to Present Analyses of Ampreloxetine and Neurogenic Orthostatic Hypotension at the 2025 International MSA CongressApril 28, 2025 | prnewswire.comRep. George Whitesides Sells Theravance Biopharma, Inc. (NASDAQ:TBPH) StockRepresentative George Whitesides (D-California) recently sold shares of Theravance Biopharma, Inc. (NASDAQ:TBPH). In a filing disclosed on April 23rd, the Representative disclosed that they had sold between $15,001 and $50,000 in Theravance Biopharma stock on March 24th. The trade occurred in the RApril 28, 2025 | marketbeat.comJPMorgan Chase & Co. Reduces Stock Position in Theravance Biopharma, Inc. (NASDAQ:TBPH)JPMorgan Chase & Co. trimmed its holdings in shares of Theravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) by 17.7% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 219,568 shares of the biopharmaceutical company's stockApril 27, 2025 | marketbeat.comTheravance Biopharma to Report First Quarter 2025 Financial Results on May 8, 2025April 24, 2025 | prnewswire.comInsider Selling: Theravance Biopharma, Inc. (NASDAQ:TBPH) SVP Sells 4,000 Shares of StockApril 24, 2025 | insidertrades.comVanguard Group Inc. Lowers Stake in Theravance Biopharma, Inc. (NASDAQ:TBPH)Vanguard Group Inc. lessened its holdings in Theravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) by 2.0% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 2,010,544 shares of the biopharmaceutical company's stock after selling 41,145 sApril 19, 2025 | marketbeat.comTrexquant Investment LP Buys 50,826 Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH)Trexquant Investment LP increased its stake in shares of Theravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) by 50.7% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 151,083 shares of the biopharmaceutical company's stApril 12, 2025 | marketbeat.comTheravance Biopharma Presents Two New Ampreloxetine Analyses in Oral Session at the American Academy of Neurology 2025 Annual MeetingApril 7, 2025 | prnewswire.comTheravance Biopharma to Participate in an Upcoming Investor ConferenceMarch 31, 2025 | prnewswire.comTheravance Biopharma to Present New Ampreloxetine Analyses in Neurogenic Orthostatic Hypotension (nOH) at the 77th Annual Meeting of the American Academy of NeurologyMarch 27, 2025 | prnewswire.comQ1 EPS Forecast for Theravance Biopharma Reduced by AnalystTheravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) - Investment analysts at Zacks Research dropped their Q1 2025 EPS estimates for shares of Theravance Biopharma in a report released on Wednesday, March 19th. Zacks Research analyst R. Department now forecasts that the biopharmaceutical companMarch 24, 2025 | marketbeat.comTheravance Biopharma, Inc. (NASDAQ:TBPH) Receives Consensus Recommendation of "Hold" from AnalystsShares of Theravance Biopharma, Inc. (NASDAQ:TBPH - Get Free Report) have been given a consensus rating of "Hold" by the five analysts that are covering the firm, Marketbeat reports. Three investment analysts have rated the stock with a hold recommendation and two have assigned a buy recommendatioMarch 23, 2025 | marketbeat.comTheravance Biopharma (NASDAQ:TBPH) Stock Crosses Above 50-Day Moving Average - What's Next?Theravance Biopharma (NASDAQ:TBPH) Share Price Crosses Above 50-Day Moving Average - What's Next?March 18, 2025 | marketbeat.comTheravance Biopharma: Clinical Progress Is Not Enough To Make It AttractiveMarch 10, 2025 | seekingalpha.comWhat is Zacks Research's Forecast for TBPH Q1 Earnings?Theravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) - Analysts at Zacks Research decreased their Q1 2026 EPS estimates for Theravance Biopharma in a research note issued to investors on Wednesday, February 26th. Zacks Research analyst R. Department now anticipates that the biopharmaceutical coMarch 3, 2025 | marketbeat.comTheravance Biopharma, Inc. (NASDAQ:TBPH) Q4 2024 Earnings Call TranscriptFebruary 27, 2025 | msn.comTheravance Biopharma (NASDAQ:TBPH) Announces Quarterly Earnings ResultsTheravance Biopharma (NASDAQ:TBPH - Get Free Report) released its quarterly earnings results on Wednesday. The biopharmaceutical company reported ($0.31) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.26). Theravance Biopharma had a negative net margin of 78.18% and a negative return on equity of 24.79%.February 27, 2025 | marketbeat.comWhat is HC Wainwright's Estimate for TBPH FY2024 Earnings?Theravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) - Stock analysts at HC Wainwright issued their FY2024 earnings per share estimates for Theravance Biopharma in a research report issued on Tuesday, February 25th. HC Wainwright analyst D. Tsao anticipates that the biopharmaceutical company wiFebruary 27, 2025 | marketbeat.comTheravance Biopharma reports Q4 EPS (31c), consensus (8c)February 27, 2025 | markets.businessinsider.comTheravance Biopharma, Inc. (TBPH) Q4 2024 Earnings Call TranscriptFebruary 26, 2025 | seekingalpha.comTheravance Biopharma, Inc. Reports Record Fourth Quarter and Full Year 2024 Financial ResultsFebruary 26, 2025 | prnewswire.comResearch Analysts Set Expectations for TBPH FY2028 EarningsTheravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) - Equities researchers at HC Wainwright issued their FY2028 earnings estimates for shares of Theravance Biopharma in a research note issued to investors on Tuesday, February 25th. HC Wainwright analyst D. Tsao anticipates that the biopharmaceFebruary 26, 2025 | marketbeat.comEarnings To Watch: Theravance Biopharma Inc (TBPH) Reports Q4 2024 ResultFebruary 25, 2025 | finance.yahoo.comTheravance Biopharma, Inc. (NASDAQ:TBPH) Given Average Recommendation of "Hold" by BrokeragesShares of Theravance Biopharma, Inc. (NASDAQ:TBPH - Get Free Report) have been given an average recommendation of "Hold" by the five analysts that are covering the company, MarketBeat Ratings reports. Three research analysts have rated the stock with a hold rating and two have issued a buy ratingFebruary 25, 2025 | marketbeat.comTheravance Biopharma (NASDAQ:TBPH) Earns "Buy" Rating from HC WainwrightHC Wainwright reaffirmed a "buy" rating and set a $15.00 target price on shares of Theravance Biopharma in a research note on Tuesday.February 25, 2025 | marketbeat.comTheravance Biopharma (NASDAQ:TBPH) Shares Cross Above 50 Day Moving Average - Here's WhyTheravance Biopharma (NASDAQ:TBPH) Stock Price Passes Above Fifty Day Moving Average - Here's WhyFebruary 25, 2025 | marketbeat.comTheravance Biopharma to Participate in an Upcoming Investor ConferenceFebruary 20, 2025 | prnewswire.comTheravance Biopharma (TBPH) Projected to Post Quarterly Earnings on MondayTheravance Biopharma (NASDAQ:TBPH) will be releasing earnings after the market closes on Monday, February 24. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=665706)February 17, 2025 | marketbeat.comTheravance Biopharma to Report Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025February 12, 2025 | prnewswire.comTheravance Biopharma to Participate in an Upcoming Investor ConferenceFebruary 5, 2025 | prnewswire.comTheravance Biopharma (NASDAQ:TBPH) Reaches New 52-Week High - Here's WhyTheravance Biopharma (NASDAQ:TBPH) Hits New 1-Year High - Here's WhyJanuary 25, 2025 | marketbeat.com Get Theravance Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for TBPH and its competitors with MarketBeat's FREE daily newsletter. Email Address TBPH Media Mentions By Week TBPH Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TBPH News Sentiment▼1.340.65▲Average Medical News Sentiment TBPH News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TBPH Articles This Week▼52▲TBPH Articles Average Week Get Theravance Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for TBPH and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies SUPN News GLPG News ARQT News AGIO News SDGR News IRON News BHC News CNTA News INDV News BHVN News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:TBPH) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredWarning: Prepare to Be Shocked by These PayoutsThere's a strategy out there paying up to 70% on tech stocks like Amazon, Tesla, and Microsoft—stocks that don...Investors Alley | SponsoredThe Prophet's Newest PredictionA storm is brewing in the markets: new tariffs, recession warnings, and panic in the headlines. That’s when pu...Stansberry Research | SponsoredA new financial chapter Porter Stansberry says what happened last week could become the defining legacy of his financial publishing ca...Porter & Company | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredTrump’s Bitcoin Reserve is No Accident…How everyday investors are building crypto wealth (step-by-step guide) Don't wait. The window for maximum g...Crypto 101 Media | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredSilver Is the New Oil—And the World’s Running DryElon's Next Market Move Could Send Silver Soaring Every industry Elon Musk touches explodes—from Tesla to S...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Theravance Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Theravance Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy TBPH Stock Free TBPH Stock Alerts